Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences' Alzheimer's disease program takes on renewed significance following positive aducanumab news

GlobeNewswire December 10, 2019

Aducanumab is good; next generation Alzheimer's disease therapies will be better

GlobeNewswire December 5, 2019

ProMIS Neurosciences Completes First Closing of Private Placement

Canada NewsWire November 18, 2019

ProMIS Neurosciences Announces Third Quarter 2019 Results

Canada NewsWire November 14, 2019

ProMIS Neurosciences Undertaking $6.5M Private Placement

Canada NewsWire November 13, 2019

ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease

PR Newswire November 7, 2019

ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease

Canada NewsWire October 24, 2019

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43

Canada NewsWire October 23, 2019

ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau

Canada NewsWire October 17, 2019

ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy

Canada NewsWire October 8, 2019

ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit

PR Newswire September 16, 2019

ProMIS Neurosciences to Present at HC Wainwright Investment Conference

Canada NewsWire September 3, 2019

ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board

Canada NewsWire August 27, 2019

ProMIS Neurosciences Announces Second Quarter 2019 Results

PR Newswire August 13, 2019

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

Canada NewsWire July 24, 2019

ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019

Canada NewsWire July 18, 2019

ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

Canada NewsWire July 10, 2019

ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports

Canada NewsWire July 9, 2019

Advanced Alzheimer’s Treatment Showcased at Keystone Symposium

Jonathon Brown June 28, 2019

ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

Canada NewsWire June 27, 2019